Arcellx, Inc. is a Pharmaceuticals company based in the United States of America. With a Risk Rating Score of 26.9, the company is considered to have a Medium Risk assessment. Specializing in reimagining cell therapy, Arcellx focuses on developing immunotherapies for patients battling cancer and other incurable diseases. The company is committed to ESG principles to ensure environmental, sustainability, and governance standards are met in their operations.